Diagnosed with FSGS?

Lumina Logo - final-2.png

Consider participating in a clinical study investigating a potential treatment for Focal Segmental Glomerulosclerosis (FSGS) with and without Nephrotic Syndrome

FSGS: a rare kidney disease


Chemokine Receptor 2 (CCR2) normally causes immune cells to move into a part of the body that is inflamed. In addition, certain cells in your kidney may be negatively affected by CCR2 which leads to high protein levels in your urine.

The medication being studied, CCX140-B is designed to block CCR2. When CCX140-B is given, it blocks CCR2 and may reduce injury of these kidney cells

Participate in the study


CCX 140-B is an investigational medication being studied to learn if it is safe and effective for the treatment of FSGS with or without Nephrotic Syndrome.

The study medication has been tested before in patients with diabetes with kidney disease and abnormal protein excretion in the urine.

Find out if you are eligible


If tests have detected abnormally high protein in your urine, it may be one of the signs that led to your diagnosis of FSGS and Nephrotic syndrome.

If you meet the requirements, you may be eligible to participate in the LUMINA study.

For more detailed information about the study of FSGS alone, go to:

For the study in FSGS and Nephrotic Syndrome go to:


Are You Eligible to Participate?

Take the survey, and get a referral to a study site near you.

Are you 18 years of age or older? *
Have you ever been given a diagnosis of FSGS with, or without, nephrotic syndrome? *
Have you had a kidney biopsy? *
Have tests shown you have too much protein in your urine? *

If you answered “yes” to all of these questions you may be eligible

The information you provide will not be stored, but only used to determine if you are eligible for the study. Please note you are only eligible to take this survey or participate in the study if you are over 18 years old.